SlideShare una empresa de Scribd logo
1 de 16
Scientific  Supervisors : Prof. Dr.B.I.Polyakov Dr.M.Y. Fedyanin Presented by: Dr.Ye Hlaing Bwar Significance of Prognostic Factors in Epithelial Ovarian Cancer M.V.LOMONOSOV MOSCOW STATE UNIVERSITY Faculty of Basic Medicine
Ovarian cancer is the fifth leading cause of death from cancer in women. Leading cause of death from gynecological cancer   in United State .
Mortality  from Ovarian Cancer ,[object Object],[object Object],[object Object],[object Object]
Prognostic factor  -  any measurement  available at the time of surgery or diagnosis  that correlates with disease-free or overall  survival  and, as a result, is able to correlate  with the natural history of the disease.  (>90%) Epithelial Ovarian Cancer
Prognostic Factors in Epithelial Ovarian Cancer Prognostic Factors -  Age -  Histology -  Grade -  Stage(FIGO)  -  ECOG performance status  -  CA125 -  Ascites -  Residual disease -  Ploidy -  Type of chemotherapy - Interval debulking
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Diagnosis
Aim of Study To indentify the statistical significance prognostic factors in epithelial ovarian cancer treated with surgery and primary systemic chemotherapy.
[object Object],[object Object],[object Object],[object Object],Objectives of study
Patients and Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patients and Methods Statistical Analysis -  MedCalc software (version 9.6) -  x 2  test to compare distribution of baseline characteristics -  Fisher’s exact test where appropriate -  Kaplan-Meier method for survivals, log-rank test for comparison & Cox  proportional hazard regression models for multivariate analysis Follow-up  -  every 3 months for 1 st  two years, every 6 months for next 3 yrs &  annually thereafter
Distribution of Patients Baseline Characteristics (n=55)
5 year Overall Survival Rate (n=55)
Univariate Analysis of Prognostic Factors
Significance in  Sub-group of prognostic factor
CONCLUSION 1.  Statistical Significance of Prognostic Factors Age  (P=0.028). Histology  (P=0.035). FIGO stage  (P=0.022). Ascites  (P=0.028). ,[object Object],[object Object],[object Object],2. ,[object Object],[object Object],[object Object],[object Object],3.
Thank You!

Más contenido relacionado

La actualidad más candente

Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...CSCJournals
 
Pelvic insufficiency fracture
Pelvic insufficiency fracturePelvic insufficiency fracture
Pelvic insufficiency fractureKanhu Charan
 
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...Apollo Hospitals
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...European School of Oncology
 
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...Hugo Raul Castro Salguero
 
Dr naseer baloch journal club
Dr naseer baloch journal clubDr naseer baloch journal club
Dr naseer baloch journal clubDrHafeez Yaqoob
 
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...Health Sciences North | Horizon Santé Nord
 
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
632   0713 - ferreyro bl - predictive score for estimating cancer after venou...632   0713 - ferreyro bl - predictive score for estimating cancer after venou...
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...Debourdeau Phil
 
Innovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to HopeInnovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to HopeChristopher Kanski
 
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer MoonshotOvarian Cancer Research Fund Alliance
 
Management of Early Breast Cancer
Management of Early Breast CancerManagement of Early Breast Cancer
Management of Early Breast CancerPhilip Mensah
 
Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Zeena Nackerdien
 
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...iosrjce
 
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineBevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineKishore Chandra Korada
 

La actualidad más candente (19)

Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
 
Pelvic insufficiency fracture
Pelvic insufficiency fracturePelvic insufficiency fracture
Pelvic insufficiency fracture
 
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
 
Dr. Lucas Minig
Dr. Lucas MinigDr. Lucas Minig
Dr. Lucas Minig
 
Ovarian cancer
Ovarian cancerOvarian cancer
Ovarian cancer
 
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
 
International Journal of Hepatology & Gastroenterology
International Journal of Hepatology & GastroenterologyInternational Journal of Hepatology & Gastroenterology
International Journal of Hepatology & Gastroenterology
 
Dr naseer baloch journal club
Dr naseer baloch journal clubDr naseer baloch journal club
Dr naseer baloch journal club
 
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
 
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
632   0713 - ferreyro bl - predictive score for estimating cancer after venou...632   0713 - ferreyro bl - predictive score for estimating cancer after venou...
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
 
Innovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to HopeInnovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to Hope
 
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
 
IJET-V3I2P22
IJET-V3I2P22IJET-V3I2P22
IJET-V3I2P22
 
Management of Early Breast Cancer
Management of Early Breast CancerManagement of Early Breast Cancer
Management of Early Breast Cancer
 
Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)
 
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
 
Cancer de la región anal 2019
Cancer de la región anal 2019Cancer de la región anal 2019
Cancer de la región anal 2019
 
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineBevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
 

Similar a Yehlaingbwar

Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docxOriginal StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docxvannagoforth
 
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce
 
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERKanhu Charan
 
Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1guest108e832
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...semualkaira
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...semualkaira
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...semualkaira
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...eshaasini
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptMusaibMushtaq
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningdaranisaha
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningsemualkaira
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningsemualkaira
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningJohnJulie1
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningAnonIshanvi
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningEditorSara
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningNainaAnon
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewZeena Nackerdien
 
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningEvolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningsummer elmorshidy
 
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...AI Publications
 

Similar a Yehlaingbwar (20)

Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docxOriginal StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
 
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
 
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
 
Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overview
 
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningEvolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
 
The Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin WisemanThe Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin Wiseman
 
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
 

Último

Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
ROLES IN A STAGE PRODUCTION in arts.pptx
ROLES IN A STAGE PRODUCTION in arts.pptxROLES IN A STAGE PRODUCTION in arts.pptx
ROLES IN A STAGE PRODUCTION in arts.pptxVanesaIglesias10
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfPatidar M
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptshraddhaparab530
 
Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationRosabel UA
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...JojoEDelaCruz
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management systemChristalin Nelson
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfErwinPantujan2
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfTechSoup
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONHumphrey A Beña
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptx
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptxMusic 9 - 4th quarter - Vocal Music of the Romantic Period.pptx
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptxleah joy valeriano
 

Último (20)

Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
ROLES IN A STAGE PRODUCTION in arts.pptx
ROLES IN A STAGE PRODUCTION in arts.pptxROLES IN A STAGE PRODUCTION in arts.pptx
ROLES IN A STAGE PRODUCTION in arts.pptx
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdf
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.ppt
 
Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translation
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...
ENG 5 Q4 WEEk 1 DAY 1 Restate sentences heard in one’s own words. Use appropr...
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management system
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
 
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptxFINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptx
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptxMusic 9 - 4th quarter - Vocal Music of the Romantic Period.pptx
Music 9 - 4th quarter - Vocal Music of the Romantic Period.pptx
 
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxLEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
 

Yehlaingbwar

  • 1. Scientific Supervisors : Prof. Dr.B.I.Polyakov Dr.M.Y. Fedyanin Presented by: Dr.Ye Hlaing Bwar Significance of Prognostic Factors in Epithelial Ovarian Cancer M.V.LOMONOSOV MOSCOW STATE UNIVERSITY Faculty of Basic Medicine
  • 2. Ovarian cancer is the fifth leading cause of death from cancer in women. Leading cause of death from gynecological cancer in United State .
  • 3.
  • 4. Prognostic factor - any measurement available at the time of surgery or diagnosis that correlates with disease-free or overall survival and, as a result, is able to correlate with the natural history of the disease. (>90%) Epithelial Ovarian Cancer
  • 5. Prognostic Factors in Epithelial Ovarian Cancer Prognostic Factors - Age - Histology - Grade - Stage(FIGO) - ECOG performance status - CA125 - Ascites - Residual disease - Ploidy - Type of chemotherapy - Interval debulking
  • 6.
  • 7. Aim of Study To indentify the statistical significance prognostic factors in epithelial ovarian cancer treated with surgery and primary systemic chemotherapy.
  • 8.
  • 9.
  • 10. Patients and Methods Statistical Analysis - MedCalc software (version 9.6) - x 2 test to compare distribution of baseline characteristics - Fisher’s exact test where appropriate - Kaplan-Meier method for survivals, log-rank test for comparison & Cox proportional hazard regression models for multivariate analysis Follow-up - every 3 months for 1 st two years, every 6 months for next 3 yrs & annually thereafter
  • 11. Distribution of Patients Baseline Characteristics (n=55)
  • 12. 5 year Overall Survival Rate (n=55)
  • 13. Univariate Analysis of Prognostic Factors
  • 14. Significance in Sub-group of prognostic factor
  • 15.